This second volume of Strategic Patent and Commercialization Journey of Nemonoxacin examines the molecule's progression through the most consequential stages of its development. Moving from late-phase clinical evaluation to regulatory negotiation, manufacturing scale-up, and early post-approval deployment, the narrative situates Nemonoxacin within the broader scientific and policy environment shaping antimicrobial innovation.
Central to this account is TaiGen's systematic construction of a durable intellectual property and life-cycle management strategy. Through data-driven patent generation, jurisdiction-specific protection plans, and targeted extensions of clinical and formulation claims, the company sought to secure long-term market viability in a competitive therapeutic domain.
Set against shifting regional politics and Taiwan's growing biotech ambitions, this volume offers a close, unvarnished look at how a medicine survives the long arc from development to market - and how a company uses every lever available, from clinical evidence to life-cycle management, to keep that arc intact.
For readers interested in the human and strategic story behind drug development, it is both a case study and a record of a pivotal moment in Taiwan's scientific history.
By:
Chi-Hsin Richard King Imprint: Chi-Hsin Richard King Dimensions:
Height: 229mm,
Width: 152mm,
Spine: 10mm
Weight: 349g ISBN:9781971588230 ISBN 10: 1971588237 Pages: 132 Publication Date:25 March 2026 Audience:
General/trade
,
ELT Advanced
Format:Hardback Publisher's Status: Active